Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery

NCT00798447 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

GI Cancer

Interventions

DRUG: MLF 541
DRUG: Lipofundin MCT

Sponsor

B. Braun Melsungen AG

Collaborators

[object Object]